NVS241220C125000
- 0.15
- 0.000.00%
Novartis AG Newsroom
Novartis AG (NVS): A Bull Case Theory
Why Novartis AG (NVS) Is One of the Most Profitable Pharmaceutical Stocks Right Now?
Wedbush Assumes Coverage of Voyager With Outperform Rating
Bernstein Keeps Their Buy Rating on Novartis AG (NOVN)
Novartis (NVS.US) has received approval from the European Commission for its important small molecule drug, which is expected to transform the treatment of early-stage breast cancer.
Novartis will continue to evaluate the long-term outcomes of NATALEE patients, including overall survival.
European Commission Approves Products by BeiGene, GSK and Novartis
The European Commission Has Approved Novartis' Kisqali (Ribociclib) In Combination With An Aromatase Inhibitor For The Adjuvant Treatment Of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer At High Risk...
Novartis' Early Breast Cancer Drug Gets Approval From EU Commission
Octavian AG Lifts Price Target on Novartis, Maintains Hold Recommendation
Novartis (NVS.US) has launched hydrochloride acyclovir tablets in the domestic market, indicated for IgA nephropathy.
Acarbose is an investigational high-potency selective oral ETA (endothelin A) receptor antagonist, activation of the ETA receptor results in increased proteinuria, which is associated with kidney damage, fibrosis, and loss of renal function in IgA nephropathy.
Top Gap Ups and Downs on Monday: SMCI, ZM, GFI and More
BMO Capital Upgrades Novartis AG(NVS.US) to Buy Rating, Raises Target Price to $156
6-K: Novartis Upgrades Mid-Term Guidance
TD Cowen Maintains Novartis AG(NVS.US) With Hold Rating
Global Equities Roundup: Market Talk
Novartis's Midterm Guidance Lift Still Needs to Convince the Market -- Market Talk
Barclays Remains a Sell on Novartis AG (NOVN)
Novartis AG (NOVN) Gets a Buy From Kepler Capital
Are Hedge Funds Banking on Novartis AG (NVS)'s Core Income Growth?
Novartis Raises Sales Outlook for Mid-Term, Acquires Kate Therapeutics